Please login to the form below

Not currently logged in
Email:
Password:

UniQure

This page shows the latest UniQure news and features for those working in and with pharma, biotech and healthcare.

UniQure edges closer to haemophilia B gene therapy OK

UniQure edges closer to haemophilia B gene therapy OK

That gives UniQure a shot at being first to market, and the positive results sparked a 10% increase in its share price ahead of the weekend. ... We are extremely pleased with these updated data,” said UniQure’s chief medical officer Robert Gut

Latest news

  • J&J bolsters gene therapy unit with $100m MeiraGTx deal J&J bolsters gene therapy unit with $100m MeiraGTx deal

    In Europe, the first approved gene therapy – UniQure’s Glybera – was launched way back in 2012 but was withdrawn five years later for commercial reasons.

  • UniQure cleared to start Huntington gene therapy trial UniQure cleared to start Huntington gene therapy trial

    The FDA has given UniQure the nod to start a gene therapy trial in Huntington’s disease, the first for the company involving a central nervous system disease. ... UniQure says AMT-130 is the first adeno-associated virus (AAV) based gene therapy to be

  • UniQure skyrockets on haemophilia B gene therapy data UniQure skyrockets on haemophilia B gene therapy data

    Competition with Pfizer and Spark rival heats up. It’s a measure of the anticipation about gene therapy that data positive data in three haemophilia patients caused UniQure shares to close ... The phase 2b results for UniQure’s AMT-061 candidate for

  • Pfizer enters late-stage haemophilia B gene therapy trial Pfizer enters late-stage haemophilia B gene therapy trial

    Race is on to free patients of regular injections. Pfizer has begun testing investigational gene therapy fidanacogene elaparvovec for the treatment of haemophilia B, triggering a race against Dutch biotech UniQure. ... The news of the phase III programme

  • VC raises new €270m fund for European biotechs VC raises new €270m fund for European biotechs

    It currently has around 25 companies in its portfolio, including Dutch gene therapy specialist UniQure, UK women’s health start-up KaNDy Therapeutics and US biotech Argos Therapeutics which as an

More from news
Approximately 10 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... The EMA approved the world’s first ever

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Unfortunate message. Some of these thorny problems were encapsulated in uniQure’s recent decision not to seek an extension to its five-year European marketing authorisation - which expires in October - for

  • Pharma deals in April 2015 Pharma deals in April 2015

    BMS will also take a 4.9% equity stake in uniQure which will cost around $32m, with another 5% ownership scheduled before the end of the year (at 10% premium). ... UniQure also stands to receive research, development and regulatory milestones, including

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    32, 700. uniQure NV/ Bristol-Myers Squibb. R&D collaboration plus equity investment.

  • Anticipating the future in healthcare Anticipating the future in healthcare

    The technology was licensed from the Dutch bio company uniQure BV by Chiesi, a mid-sized, family-owned pharma company based in Parma, Italy.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Solaris Health looks at the gene therapy revolution

    There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics